Tessa Romero
Stock Analyst at JP Morgan
(4.11)
# 450
Out of 5,173 analysts
81
Total ratings
44.44%
Success rate
17.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics | Maintains: Overweight | $34 → $45 | $29.80 | +51.01% | 12 | Mar 17, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $74 → $75 | $60.95 | +23.05% | 7 | Mar 17, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $47 → $50 | $43.66 | +14.52% | 7 | Mar 16, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $31 → $34 | $20.99 | +61.98% | 12 | Mar 4, 2026 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $17 → $16 | $17.87 | -10.46% | 8 | Jan 20, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $60 → $62 | $54.42 | +13.93% | 4 | Jan 9, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $20 → $25 | $28.11 | -11.06% | 8 | Jan 6, 2026 | |
| OCS Oculis Holding AG | Initiates: Overweight | $38 | $24.60 | +54.47% | 1 | Dec 19, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $47 → $15 | $8.74 | +71.62% | 8 | Nov 20, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Underweight | $261 → $263 | $4.34 | +5,959.91% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.47 | - | 5 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $10 | $5.54 | +80.51% | 2 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $8.45 | +349.70% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.67 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $12.83 | +126.03% | 3 | Aug 13, 2024 |
Edgewise Therapeutics
Mar 17, 2026
Maintains: Overweight
Price Target: $34 → $45
Current: $29.80
Upside: +51.01%
Cytokinetics
Mar 17, 2026
Maintains: Overweight
Price Target: $74 → $75
Current: $60.95
Upside: +23.05%
Scholar Rock Holding
Mar 16, 2026
Maintains: Overweight
Price Target: $47 → $50
Current: $43.66
Upside: +14.52%
ACADIA Pharmaceuticals
Mar 4, 2026
Maintains: Overweight
Price Target: $31 → $34
Current: $20.99
Upside: +61.98%
Dyne Therapeutics
Jan 20, 2026
Maintains: Neutral
Price Target: $17 → $16
Current: $17.87
Upside: -10.46%
Xenon Pharmaceuticals
Jan 9, 2026
Maintains: Overweight
Price Target: $60 → $62
Current: $54.42
Upside: +13.93%
Agios Pharmaceuticals
Jan 6, 2026
Maintains: Neutral
Price Target: $20 → $25
Current: $28.11
Upside: -11.06%
Oculis Holding AG
Dec 19, 2025
Initiates: Overweight
Price Target: $38
Current: $24.60
Upside: +54.47%
Biohaven
Nov 20, 2025
Maintains: Overweight
Price Target: $47 → $15
Current: $8.74
Upside: +71.62%
Rocket Pharmaceuticals
Nov 18, 2025
Downgrades: Underweight
Price Target: $261 → $263
Current: $4.34
Upside: +5,959.91%
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $2.47
Upside: -
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $5.54
Upside: +80.51%
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $8.45
Upside: +349.70%
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $8.67
Upside: -
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $12.83
Upside: +126.03%